Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 88 Dimensions

Readers on

mendeley: 42 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 11 X posts from 6 X users, with an upper bound of 22,780 followers.

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma https://t.co/MR2XFr2oTd

06 Nov 2020

Reply Repost Favourite

RT @Dharmisha: “Nivolumab plus ipilimumab gained 0.70–0.76 QALYs compared with sunitinib” but may not be cost effective for UK in first lin…

13 Dec 2018

Reply Repost Favourite

“Nivolumab plus ipilimumab gained 0.70–0.76 QALYs compared with sunitinib” but may not be cost effective for UK in first line setting but 1.17yrs gained with Ipi + Nivo. Due to costing in mg/kg. Analysis has weakness e.g toxicity not comparable, as explain

13 Dec 2018

Reply Repost Favourite

#JITC Research: Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma https://t.co/I4doEo7JoM https://t.co/Kh6VAr5RkF

13 Dec 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.